Shanghai HaiHe Pharmaceutical Co., Ltd and 3D Medicines announced on April 28, the two sides reached strategic collaboration in FGFR inhibitors (code-named “HH185”) that from HaiHe Pharmaceutical and 3D Medicines have the right to start the research, production and commercialization of HH185 in mainland China, Hong Kong, Macao and Taiwan for the treatment of tumor and pulmonary fibrosis.
HH185 was synthesized by Medicilon and completed the preclinical pharmacokinetic research and safety evaluation. It will be a progress in the development of anti-cancer drugs.
HH185 is a small molecule inhibitor targeting fibroblast growth fact receptor 1, 2, 3 (FGFR 1, 2, 3), and it was awarded the CFDA clinical approval in January 2018. The research of HH185 was developed by HaiHe Pharmaceutical with Shanghai Institute of Medicine, Chinese Academy of Sciences and the clinical development was done by HaiHe Pharmaceutical.
Preclinical studies have shown that HH185 can significantly inhibit the proliferation of FGFR1, 2, 3-mediated tumor cells in vitro and play a significant anti-tumor effect in the xenograft model of solid tumor. HH185 has strong anti-tumor activity, good characteristics of PD-PK, low toxicity, high bioavailability, and CSF1-R targeting, suitable for combination with PD-1 / PD-L1 in the field of tumor immunotherapy.